Figure 1.

Incidence rates of lymphoma in the tofacitinib clinical program by 6‐month time intervals. Exposure and incidence rates are shown for each discrete 6‐month time period. ^a = The final reporting period (>54 months) was expanded such that there were at least 1,000 patient‐years of exposure for this period. The final interval included patients with >54 to 96 months of exposure. Since this analysis was performed, a further data cut including exposure up to 105 months has become available. During this time, no additional lymphoma events have occurred. 95% CI = 95% confidence interval.